PMN

ProMIS Neurosciences Inc.

BS score —UNSCOREDPHASE1 · mkt cap $112.1M · rev ttm $0

drug hypothesis

PMN310 modulates Unknown - not disclosed in provided data to treat Unknown - trial conducted in healthy participants (Phase 1a safety/PK study).

moa:Unknown - not disclosed in provided data

score breakdown

trial design0

base rate disconnect0

language red flags0

composite—

valuation analysis

market cap$112.1M

revenue ttm$0

phasePHASE1

historical base rate—

disconnect ratio—

lead trialNCT06105528

meta

cik0001374339

first discovered2026-04-10

last updated2026-04-10

statusACTIVE

llm modelminimax/minimax-m2.5:free

extracted at2026-04-10

trial design

Phase 1a randomized double-blind study in 40 healthy volunteers, not placebo-controlled, evaluating safety and pharmacokinetics including serum PK parameters (AUCinf, AUClast, Cmax, Tmax, T1/2, CL, Vd) and CSF concentrations over 85 days follow-up

primary endpoint:Incidence of Treatment Emergent Adverse Events (85 days)

claimed differentiation

Not provided in clinical trial data

language red flags

Insufficient data provided to assess - clinical trial entry alone does not contain company statements, target information, mechanism of action, or development strategy